[Federal Register Volume 84, Number 195 (Tuesday, October 8, 2019)]
[Notices]
[Page 53743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21965]



[[Page 53743]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent application listed below may be obtained by 
communicating with Sury Vepa, Ph.D., J.D., Senior Licensing and 
Patenting Manager, National Center for Advancing Translational 
Sciences, NIH, 9800 Medical Center Drive, Rockville, MD 20850, Phone: 
301-827-7181, or email [email protected]. A signed Confidential 
Disclosure Agreement will be required to receive copies of unpublished 
patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Inhibitors of Phosphoinositide 3-Kinase and Histone Deacetylase for 
Treatment of Cancer

    Description of Technology: The invention includes compounds that 
act as dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone 
deacetylase (HDAC), including a core containing a quinazoline moiety or 
a quinazolin-4(3H)-one moiety, a kinase hinge binding moiety, and a 
histone deacetylase pharmacophore, a pharmaceutically acceptable salt 
thereof, a prodrug thereof, or solvate thereof. The present invention 
also provides compounds that are selective inhibitors of histone 
deacetylase inhibitor that include a core containing a quinazolin-
4(3H)-one moiety and a histone deacetylase pharmacophore.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Novel therapeutics for cancers neurodegenerative diseases.
    Competitive Advantages:
     Novel dual inhibitor compounds of this invention have a 
commercial advantage over those currently known because they can act as 
selective and dual inhibitors of specific isoforms of HDAC (such as 
HDAC6) and PI3K (such as PI3K[delta]) potentially providing better 
toxicity profile and therefore bigger therapeutic window.
    Development Stage:
     Pre-Clinical (compound optimization and in vivo 
validation).
    Inventors:
     Grewal, Gurmit; Thakur, Ashish; Tawa, Gregory James; 
Ferrer, Marc; and Simeonov, Anton M.
    Intellectual Property: 1. INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE 
AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER, PCT Patent Application 
NO. PCT/US2018/038507 filed on June 20, 2018 (HHS Ref. No. E-104-2017).
    Licensing Contact: Sury Vepa, Ph.D., J.D. Phone: 301-827-7181, or 
email [email protected].

    Dated: October 1, 2019.
Lillianne M. Portilla Weingarten,
Technology Development Coordinator, National Center for Advancing 
Translational Sciences.
[FR Doc. 2019-21965 Filed 10-7-19; 8:45 am]
BILLING CODE 4140-01-P